Wang Ying, Wang Bo, Li Peng, Zhang Qi, Liu Pinan
a Beijing Neurosurgical Institute, Capital Medical University , Beijing , China.
b Department of Neurosurgery , Beijing Tiantan Hospital, Capital Medical University , Beijing , China.
Neurol Res. 2017 Dec;39(12):1086-1093. doi: 10.1080/01616412.2017.1376494. Epub 2017 Sep 22.
Objective To study the function and potential mechanism of RAC1 inhibitors in NF2-associated schwannoma. Methods In this study, we the downregulation of RAC1 activity and tumor cell phenotypes by RAC1 inhibitor NSC23766 in vitro. And we further validated the anti-proliferation effect by this RAC1 inhibitor in subcutaneous xenograft tumor model and sciatic nerve model. Results Pharmacological inhibition of RAC1 could significantly inhibit the proliferation of both RT4 cells and human NF2-associated primary schwannoma cells by inducing apoptosis. Pharmacological inhibition of RAC1 effectively reduced Rac1 activity and down-regulated the pathway downstream of Rac. Moreover, pharmacological inhibition of RAC1 showed a potential antitumor effect, with low toxicity in vivo. Conclusion RAC1 inhibitors may play a therapeutic role in patients with schwannoma.
目的 研究RAC1抑制剂在神经纤维瘤病2型(NF2)相关神经鞘瘤中的作用及潜在机制。方法 在本研究中,我们在体外通过RAC1抑制剂NSC23766下调RAC1活性和肿瘤细胞表型。并且我们在皮下异种移植瘤模型和坐骨神经模型中进一步验证了该RAC1抑制剂的抗增殖作用。结果 RAC1的药理学抑制可通过诱导凋亡显著抑制RT4细胞和人NF2相关原发性神经鞘瘤细胞的增殖。RAC1的药理学抑制有效降低了Rac1活性并下调了Rac下游通路。此外,RAC1的药理学抑制显示出潜在的抗肿瘤作用,在体内毒性较低。结论 RAC1抑制剂可能对神经鞘瘤患者发挥治疗作用。